Assembly Biosciences, Inc. financial data

Symbol
ASMB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Two Tower Place, 7 Th Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
VENTRUS BIOSCIENCES INC (to 7/11/2014)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 262 % -47.9%
Debt-to-equity 259 % +314%
Return On Equity -127 % -7.82%
Return On Assets -35.4 % +51.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.5M shares +36.9%
Common Stock, Shares, Outstanding 7.46M shares +36%
Entity Public Float 69M USD +15%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 6M shares +31.2%
Weighted Average Number of Shares Outstanding, Diluted 6M shares +31.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 55.9M USD +14.4%
General and Administrative Expense 18M USD -21.4%
Operating Income (Loss) -45.4M USD +29.7%
Nonoperating Income (Expense) 5.57M USD +61.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.61M USD +33.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -40.2M USD +34.4%
Earnings Per Share, Basic -6.69 USD/shares +50%
Earnings Per Share, Diluted -6.69 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.3M USD +93.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 116M USD -13.7%
Property, Plant and Equipment, Net 284K USD -26.2%
Operating Lease, Right-of-Use Asset 3.07M USD +31.2%
Other Assets, Noncurrent 312K USD 0%
Assets 119M USD -12.9%
Accounts Payable, Current 585K USD +26.9%
Employee-related Liabilities, Current 6.48M USD +18.1%
Accrued Liabilities, Current 6.86M USD +19.5%
Contract with Customer, Liability, Current 37.6M USD +21.7%
Liabilities, Current 47.8M USD +21.9%
Contract with Customer, Liability, Noncurrent 35.4M USD -36.1%
Operating Lease, Liability, Noncurrent 2.63M USD +134%
Liabilities 85.8M USD -10.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -211K USD -160%
Retained Earnings (Accumulated Deficit) -826M USD -5.11%
Stockholders' Equity Attributable to Parent 33.4M USD -18.8%
Liabilities and Equity 119M USD -12.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.4M USD +21.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +72.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 7.46M shares +36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.09M USD +87.8%
Deferred Tax Assets, Valuation Allowance 212M USD +4.54%
Deferred Tax Assets, Gross 212M USD +4.6%
Operating Lease, Liability 3.09M USD +31.9%
Payments to Acquire Property, Plant, and Equipment 14K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.3M USD +33.4%
Lessee, Operating Lease, Liability, to be Paid 3.93M USD +52.5%
Property, Plant and Equipment, Gross 595K USD -75.5%
Operating Lease, Liability, Current 461K USD -62.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 806K USD -31.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 751K USD -46.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 836K USD +260%
Lessee, Operating Lease, Liability, to be Paid, Year Three 834K USD
Deferred Tax Assets, Operating Loss Carryforwards 132M USD -10.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 5.18M USD +15.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 863K USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 32K USD -74.2%
Deferred Tax Assets, Net of Valuation Allowance 806K USD +24.8%
Share-based Payment Arrangement, Expense 3.12M USD -39.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%